Patients with peripheral artery disease (PAD) and diabetes who underwent treatment with a drug-coated balloon fared better than counterparts who received standard care, according to a subanalysis of the IN.PACT SFA trial.

At five years, the Zilver PTX stent proved to be a durable treatment for peripheral artery disease with sustained benefit, results presented Nov. 4 at the 2014 Vascular Interventional Advances (VIVA) meeting showed.

Shockwaves appear to have early success in breaking up calcified lesions safely. In research presented Nov. 5 at the 2014 Vascular Interventional Advances (VIVA) meeting in Las Vegas, a lithotripsy-with-balloon technique used on peripheral artery lesions resulted in all patients achieving less than 50 percent stenosis. 

Covidien announced 12-month results of the DEFINITIVE AR study, the first randomized study designed to identify the clinical benefits of plaque removal using directional atherectomy followed by drug coated balloon. The results were presented by Professor Thomas Zeller of the Universitaets-Herzzentrum, Bad Krozingen, Germany at the Vascular Interventional Advances (VIVA) 2014 conference in Las Vegas, Nev.

Each year, some 2,000 babies are born in the U.S. with a genetic heart condition, known as long QT syndrome. If not diagnosed in time, babies with long QT syndrome can die from a sudden arrhythmia, or irregular heartbeat.

Infraredx, Inc., a medical device company committed to advancing the diagnosis and management of coronary artery disease, today announced that it has entered into an agreement with HealthTrust, a group purchasing organization. Under the agreement, HealthTrust will offer the Infraredx TVC Imaging System, a novel dual-modality intravascular imaging technology, to its member network of 1,400 acute care facilities.

CFI Medical, a leading manufacturer of innovative radiation protection products, announced CE (Conformité Européenne) approval for the Zero-Gravity Suspended Radiation Protection System Floor Unit today, paving the way for its widespread use internationally. BIOTRONIK, one of the world’s leading manufacturers of cardio- and endovascular medical devices, headquartered in Berlin, Germany, will continue to act as the exclusive distributor of Zero-Gravity outside North America.

Infraredx, Inc., a medical device company committed to advancing the diagnosis and management of coronary artery disease, today announced that its first-in-class, dual-modality intravascular imaging technology, TVC Imaging System™, and its TVC Insight™ Catheter received Shonin approval from the Japanese Ministry of Health, Labour and Welfare (MHLW).